Swiss biotech startup from Zurich, Switzerland
We present here a list of biotech startups located in the Zurich area. As the two major institutions in Zurich area are ETH Zurich and the University of Zurich, many of these startups are linked to these organizations (i.e. with spin-off companies).
Araris Biotech (see their website) – Founded: 2019 – Location: Zurich (ZH), Switzerland
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology.
Araris Biotech is backed by a strong investor syndicate: Pureos Bioventures (VC company located in Switzerland), 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq, acording to its website (Sept. 2022).
In 2020, the company raised CHF 15.2M.
In 2022, Araris ranked TOP19 at Swiss startup Award 2022 (number 5 in Biotech industry).
In 2021, Araris ranked TOP11 at Swiss startup Award 2021 (number 3 in Biotech industry).
CUTISS (see their website) – Founded (incorporated): 2017 – Location: Schlieren (ZH), Switzerland
CUTISS AG is a spin-off company from the University of Zurich. The company grows human skin in the lab for patients that suffer from skin defects (e.g. burns).
In 2020 the company raised CHF 20 million in a Series B1.
In 2022, CUTISS ranked TOP4 at Swiss startup Award 2022 (number 1 in Biotech industry).
In 2021, CUTISS ranked TOP2 at Swiss startup Award 2021 (number 1 in Biotech industry).
Numab (see their website) – Founded (incorporated): 2016 – Location: Wädenswil (ZH), Switzerland
Numab Therapeutics AG is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins.
In 2021, Numab Therapeutics completes oversubscribed CHF 100 million Series C financing2.
In 2021, Numab ranked TOP50 at Swiss startup Award 2021.
Eracal Therapeutics AG (see their webiste) – Founded (incorporated): 2018 – Location: Schlieren (ZH), Switzerland
Eracal develops a novel drug candidate Era-379 to reduce appetite.
Eracal is a spin-off from the University of Zurich and Harvard University.
The company is privately held by a biotech-specialized investor base incl. BERNINA BioInvest, Redalpine, and UZH Life Sciences Fund, acording to its website (Sept. 2022).
In 2022, CUTISS ranked TOP29 at Swiss startup Award 2022 (number 5 in Biotech industry).
More ressources:
– Swissbiotech.org
– Baselaunch.ch
Read also:
– Swiss biotech startup from Basel, Switzerland
Last update: September 21, 2022. By Xavier Gruffat, founder of Creapharma.com (pharmacist, ETH Zurich – MBA).
